Effects of carbohydrates on cancer-related fatigue and tumor growth

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K11800
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 59040:Nutrition science and health science-related
• Research Institution: Tokyo University of Science
• Principal Investigator: Yoshizawa Kazumi 東京理科大学, 薬学部薬学科, 教授 (00711532)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 肝グリコーゲン / がん関連疲労 / 糖類 / シスプラチン

Outline of Final Research Achievements

The aim of the present study was to determine whether saccharides, such as sucrose, fructose, glucose, or raffinose, could prevent CDDP-induced fatigue-like behavior in mice. Mice were administered a single dose of cisplatin (CDDP; 10 mg/kg, i.p.) or saline and then treated with saccharides (sucrose, fructose, glucose, or raffinose) daily for 4 days. CDDP-induced fatigue-like behavior was investigated by assessment of running activity on a treadmill. Administration of sucrose and glucose improved CDDP-induced fatigue-like behavior in mice, whereas administration of fructose showed only slight antifatigue effects. Although glucose-fed mice showed increased tumor growth, this was balanced out by the powerful cytotoxicity of CDDP. In contrast, raffinose improved CDDP-induced fatigue-like behavior without affecting tumor growth. Raffinose may improve patient quality of life during treatment with anticancer agents by preventing fatigue without affecting with the tumor growth.

Free Research Field

緩和医療薬学

Academic Significance and Societal Importance of the Research Achievements

シスプラチン (CDDP) を用いたがん化学療法は、肺癌、上部消化器癌、生殖器腫瘍など広範な腫瘍に適応があり、多くのがん患者が CDDP の副作用を経験している。その CDDP の副作用を予防・治療する栄養素の探索は、がん治療の継続に影響する効果不良因子への新たな予防・治療法の開発につながるものと考える。本研究の成果により、CDDP により生じる易疲労性には、グルコースをはじめとする糖類の摂取が有用であった。特に、腫瘍成長に影響を及ぼさない難消化性オリゴ糖のラフィノースは抗がん剤による副作用として生じる易疲労性を予防・治療してがん治療の継続に貢献できる可能性が示された。